CAJ | 학술논문

目的探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白依那西普对中重度寻常性银屑病的疗效.方法 2008年2月至2011年12月,诊断为中重度寻常性银屑病且经治疗疗效差的患者24例,给予抗肿瘤坏死因子靶向治疗(依那西普25 mg皮下注射,每周2次,疗程3个月),随访6个月,按银屑病面积和严重程度指数(PASI)和医师整体评估标准(PGA)对疗效进行评分.结果经依那西普治疗24周后,24例寻常性银屑病PASI减少75％的有12例(50％),1例无效,4例注射部位有红肿等不良反应.结论对于其他治疗疗效不佳的中重度寻常性银屑病患者,用抗肿瘤坏死因子治疗有效.
목적 탐토중조인Ⅱ형종류배사인자수체-항체융합단백의나서보대중중도심상성은설병적료효.방법 2008년2월지2011년12월,진단위중중도심상성은설병차경치료료효차적환자24례,급여항종류배사인자파향치료(의나서보25 mg피하주사,매주2차,료정3개월),수방6개월,안은설병면적화엄중정도지수(PASI)화의사정체평고표준(PGA)대료효진행평분.결과 경의나서보치료24주후,24례심상성은설병PASI감소75％적유12례(50％),1례무효,4례주사부위유홍종등불량반응.결론 대우기타치료료효불가적중중도심상성은설병환자,용항종류배사인자치료유효.
Objective To evaluate the efficacy profile of etanercept,a recombinant human type Ⅱ tumor necrosis factor receptor-Fc fusion protein,in patients with moderate to severe psoriasis.Methods A retrospective study was performed.This study included 24 patients with moderate to severe psoriasis vulgaris resistant to conventional therapy.They were treated with subcutaneous injection of etanercept 25 mg twice weekly for three months during February 2008 and August 2011.Six months of follow up was carried out.Clinical efficacy was evaluated by psoriasis area and severity index (PASI) and physician global assessment (PGA).Results After 24-week treatment,12 (50％) patients achieved a 75％ reduction in PASI score,1 (4.2％) patient failed to respond.Adverse reaction,such as erythematous swelling at the injection site,was observed in 4 patients.Conclusion Anti-tumor necrosis factor may be effective for the treatment of moderate to severe psoriasis recalcitrant to traditional therapy.